Exforge

Quick links to important sections

Exforge

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Exforge

What is Exforge? (Amlodipine and Valsartan)

Exforge is a prescription-only medication classified within cardiovascular medicine as a dual-acting antihypertensive agent. It is supplied for oral use as a Fixed-Dose Combination (FDC) tablet, strategically combining two distinct synthetic compounds to manage high blood pressure in adults.

Quick Facts: Amlodipine/Valsartan

Property Description
Active Ingredients Amlodipine (CCB) and Valsartan (ARB)
Form Oral Tablet (Fixed-Dose Combination)
Pharmacological Class Antihypertensive Agent
General Purpose Sustained management of hypertension (high blood pressure)
Origin Synthetic chemical compounds

Amlodipine/Valsartan: Definition and Pharmaceutical Classification

Exforge is a combination medicine that incorporates two synthetic active pharmaceutical ingredients—Amlodipine (as besylate) and Valsartan—into a single oral tablet. This unique pairing positions the product under the drug class of Angiotensin II Inhibitors with Calcium Channel Blockers. The combination of these two agents is used to improve blood pressure control, signifying that the combined approach is clinically recognized for better managing elevated pressure.

This formulation represents a Fixed-Dose Combination (FDC) product, which is a distinguishing feature, designed to exert a synergistic effect against hypertension. The combination is typically used when a patient's essential hypertension requires simultaneous targeting of multiple physiological pathways for effective control, differentiating it from single-agent therapies.

Active Ingredients and Dual-Acting Mechanism

The tablet contains Amlodipine besylate, which is pharmacologically classified as a Calcium Channel Blocker (CCB), and Valsartan, which belongs to the class of Angiotensin II Receptor Blockers (ARB). Combining these two mechanisms effectively reduces high blood pressure in patients when monotherapy has not been adequate. This reinforces the utility of the dual-acting strategy for broader control.

Amlodipine promotes the widening of blood vessels, a process of vasodilation, while Valsartan functions by blocking the vasoconstrictive effects of a natural hormone, Angiotensin II. This dual-acting approach is the basis for the drug's mechanism, offering a more comprehensive control of peripheral vascular resistance than either single ingredient alone.

Regulatory References

  1. NIH DailyMed Label for Amlodipine and Valsartan

What side effects are possible with Exforge?

Possible Side Effects and Safety Information

The safety profile of Exforge (Amlodipine/Valsartan) is formally documented in regulatory labeling and clinical surveillance reports, categorizing adverse reactions primarily by frequency and the body system affected.

Common and Expected Adverse Reactions

The frequency classification identifies specific events as common (affecting 1 to 10 in 100 patients). These reactions are frequently reported and categorized within specific system-organ classes (SOCs), including Vascular Disorders and Nervous System Disorders.

Classification Examples of Common Reactions (FDA/EMA)
Infections Nasopharyngitis, Upper Respiratory Tract Infection
Vascular Peripheral Edema (Swelling), Flushing
Nervous System Dizziness, Headache
General Fatigue, Asthenia (Weakness)

Serious Safety Constraints

The medicine is associated with serious safety constraints explicitly documented in official regulatory labeling. Use of the Valsartan component, which acts on the renin-angiotensin system, is subject to a Boxed Warning regarding Fetal Toxicity, requiring the medicine to be contraindicated during the second and third trimesters of pregnancy. Other serious adverse reactions include Angioedema (severe swelling of the face/throat) and potential for Acute Renal Failure, particularly in susceptible individuals.

Population-Specific Limitations

The drug is contraindicated or its use is avoided in patients with severe hepatic impairment and severe renal impairment (creatinine clearance le 30 mL/min), as safety and efficacy have not been fully established in these groups. Furthermore, symptomatic low blood pressure (hypotension) may occur at the start of treatment (initiation), especially in volume- or salt-depleted patients, which is a key time-related safety pattern documented in the regulatory text.

Overdose and Emergency Response

The official regulatory profile for Exforge overdose focuses on severe cardiovascular manifestations requiring immediate professional medical intervention. The primary clinical presentation of an acute overdose is marked and prolonged systemic hypotension, which stems from the excessive peripheral vasodilation caused by the Amlodipine component. Overdose may also present with corresponding heart rate abnormalities, such as reflex tachycardia or bradycardia. This profound drop in blood pressure can rapidly escalate to shock and carries a significant regulatory-documented risk of death. Due to these severe potential outcomes, government health authorities state that individuals must seek immediate medical attention for any suspected overdosage.

The officially described management strategy is defined as symptomatic and supportive treatment. No specific antidote is known for the Amlodipine component, and the Valsartan component is unlikely to be removed from the body through hemodialysis. To manage the physiological effects, supportive measures may include placing the individual in a supine position and administering an intravenous infusion of normal saline to restore blood volume. Hospital monitoring is required, encompassing continuous observation of vital signs and, potentially, ECG monitoring to address the cardiovascular instability. This focus on immediate action and supportive care reflects the high-risk classification assigned to Exforge overdosage in official labeling.

Therapeutic Uses of Exforge

Quick Facts

  • Main Use: Managing hypertension (high blood pressure).
  • Therapeutic Domain: Helps patients achieve and maintain target blood pressure levels.
  • Who it is for: Individuals whose blood pressure is not adequately managed with a single medication, or as an initial therapy when multiple agents are likely required to reach blood pressure goals.

What Exforge Treats: Main Uses and Benefits

Exforge is a medication used in the management of high blood pressure, also known as hypertension. It is intended to help lower and maintain blood pressure within a target range. Controlling high blood pressure is a key component of comprehensive cardiovascular risk management.

This medication is typically initiated for patients in two main scenarios:

  1. Add-on Therapy: For individuals whose blood pressure levels are not adequately addressed by the use of a single antihypertensive medication (monotherapy).
  2. Initial Therapy: For patients where a healthcare professional determines that multiple medications will likely be necessary from the start to achieve their blood pressure goals.

Effective management of high blood pressure with treatments like Exforge helps mitigate the risk of adverse cardiovascular events.

Eligibility and Restrictions for Use

Eligibility and Contraindications

Official regulatory documents define specific populations who must not use this medicine (contraindications) and groups for whom use is restricted or not recommended.

Exclusion Category Official Status Specific Condition
Pregnancy Contraindicated Second and third trimesters. Discontinue immediately upon detection of pregnancy.
Allergy Contraindicated Hypersensitivity to amlodipine, valsartan, or any dihydropyridine derivative.
Liver Function Contraindicated Severe hepatic impairment, biliary cirrhosis, or cholestasis.
Hemodynamic Status Contraindicated Severe hypotension, shock (including cardiogenic shock), or obstruction of the left ventricular outflow tract (e.g., high-grade aortic stenosis).
Drug-Drug Contraindicated Concomitant use with aliskiren in patients with diabetes or moderate/severe renal impairment (GFR < 60 mL/min/1.73 m^2).

Age and Other Restrictions

  • Pediatric Patients: Use is not recommended in patients under 18 years of age due to lack of established safety and efficacy data.
  • Lactation: Use is not recommended while breastfeeding.
  • Organ Impairment: Patients with severe renal impairment (GFR < 30 mL/min/1.73 m^2) are generally excluded or require extreme caution. Patients with unilateral or bilateral renal artery stenosis also require special consideration.
  • General Use: The medicine is indicated for adults whose blood pressure is not adequately controlled with the individual components alone, or for replacement therapy.

What should I know about interactions with other medicines?

Exforge (amlodipine/valsartan) can interact with several other medications, which may affect its effectiveness or increase the risk of side effects. It is essential to inform your healthcare provider about all prescription drugs, over-the-counter medicines, and supplements you are taking.

Potential Major Interactions

  • Lithium: Concurrent use with Exforge may increase lithium levels, leading to toxicity. Careful monitoring of serum lithium concentrations is necessary.
  • CYP3A4 Inhibitors and Inducers: Amlodipine is metabolized by the enzyme CYP3A4. Strong or moderate inhibitors of this enzyme (such as certain antifungal or antiretroviral medicines) can significantly increase amlodipine exposure, raising the risk of hypotension or edema. Conversely, CYP3A4 inducers may decrease amlodipine concentration, potentially reducing Exforge’s effectiveness.

Other Significant Interactions

  • Potassium Supplements and Potassium-Sparing Diuretics: Concomitant use with the valsartan component can increase the risk of hyperkalemia (high potassium levels). This includes potassium-containing salt substitutes. Monitoring of serum potassium levels is generally recommended.
  • Simvastatin: Amlodipine increases the body’s exposure to simvastatin, a cholesterol-lowering drug. To reduce the risk of muscle problems (myopathy), the dose of simvastatin should be limited when taken with Exforge, typically not exceeding 20 mg daily.
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): NSAIDs, including selective COX-2 inhibitors, may reduce the blood pressure-lowering effect of Exforge and may increase the risk of kidney function deterioration, especially in elderly or volume-depleted patients.

Mechanism of Action

How Exforge Works: Dual Mechanistic Pathway

Exforge employs two distinct, yet complementary, mechanisms of action to modulate key physiological regulatory systems. It acts simultaneously on the direct control of vascular smooth muscle tone and the hormonal signaling pathways that drive long-term pressure and volume regulation.

Modulating Vascular Smooth Muscle Contraction (Amlodipine)

One component, amlodipine, functions as a calcium channel blocker. It inhibits the transmembrane influx of extracellular calcium ions into the vascular smooth muscle cells by modulating L-type voltage-dependent calcium channels. By limiting this cellular process, amlodipine reduces the contractile force of the peripheral vessels, initiating a cascade that leads to peripheral vasodilation. This process alters the magnitude of total peripheral resistance.

Blocking the Renin-Angiotensin-Aldosterone System (Valsartan)

The second component, valsartan, is an Angiotensin II Receptor Blocker (ARB). Valsartan targets the AT1 receptors, preventing the peptide Angiotensin II, a key mediator of vasoconstriction, from binding. By engaging this mechanism, valsartan supports the regulation of pathways associated with blood vessel tightening and fluid retention, affecting the regulatory pathways for systemic arterial pressure and fluid volume.

Dosage and Administration Information

How to Use Exforge

The administration of Exforge (amlodipine/valsartan) is governed by specific instructions. The medicine is provided as a fixed-dose combination film-coated tablet for oral use, taken once daily.

Dosage and Scheduling

The standard adult dosing schedule is once daily. The dose can be increased after at least one to two weeks of therapy, with the full antihypertensive effect typically attained within two weeks of a dose change.

Usage Scenario Starting Dose (Amlodipine/Valsartan) Maximum Daily Dose
Initial Therapy 5 mg/160 mg once daily 10 mg/320 mg
Initial Therapy 5 mg/80 mg once daily 10 mg/320 mg
Replacement/Add-on Based on prior individual component doses 10 mg/320 mg

Administration Context and Adjustments

Exforge may be administered with or without food and should ideally be taken at the same time of day. For patient convenience, the fixed-dose tablet may substitute the same component doses taken previously as separate tablets.

Usage guidelines specify adjustments for certain populations:

  • Hepatic Impairment: In patients with mild to moderate hepatic impairment, the maximum recommended valsartan dose is 80 mg. Lower starting doses of amlodipine (5 mg) should be considered.
  • Renal Impairment: No initial dosage adjustment is required for patients with mild to moderate renal impairment. Slow titration is advised for those with severe impairment.

If a dose is missed, patients should take the next scheduled dose at the usual time and should not take a double dose to compensate. These instructions define the standardized, long-term protocol for the use of the medicine.

Recent Clinical Evidence

Overview of Clinical Research

Exforge is a single-pill combination of two widely studied medications, amlodipine (a calcium channel blocker) and valsartan (an angiotensin II receptor blocker). Research has focused on the combined effect of these two agents in the management of essential hypertension (high blood pressure).

Clinical trials have primarily assessed the blood pressure-lowering activity of Exforge compared to its individual components and placebo. A key finding from these trials is that the combination was associated with greater reductions in both systolic and diastolic blood pressure than either amlodipine or valsartan used alone. The majority of the antihypertensive effect was typically observed within two weeks after starting therapy or changing the dose.

Efficacy in Patient Subgroups

Studies have been conducted to observe the use of the amlodipine/valsartan combination in diverse groups of patients with hypertension, including those who may be at high risk for cardiovascular events. These observational and interventional studies included patients who were elderly, obese, or those with co-existing conditions like diabetes.

Research reports indicate that the blood pressure-lowering observations were maintained across various dosages and patient populations. Furthermore, clinical data also support the use of Exforge as initial therapy in patients who may need multiple medications to meet their blood pressure goals.

Safety and Tolerability

In controlled clinical trials, the most commonly reported adverse events with Exforge included swelling in the extremities (peripheral edema), nasopharyngitis, upper respiratory tract infection, and dizziness. The overall discontinuation rate due to side effects was reported to be low. The safety profile is generally consistent with the known profiles of the individual components.

Frequently Asked Questions (FAQ)

Common questions about Exforge (FAQ)


Q: What happens if I forget to take my Exforge dose?

A: Official administration instructions state that if a dose is missed, a person should take the next scheduled dose at the usual time. It is important not to take a double dose to compensate for the forgotten dose. Consistent daily use supports the prescribed management of blood pressure.


Q: Can I take Exforge if I have diabetes?

A: Exforge is included in studies involving patients with co-existing conditions, including diabetes. However, regulatory documents note a specific contraindication for the use of the valsartan component with aliskiren in patients who also have diabetes or moderate-to-severe kidney problems. Regulatory warnings indicate that certain medication combinations may need to be avoided or reviewed.


Q: Can Exforge be taken on an empty stomach?

A: Yes. According to the official prescribing information, Exforge may be taken with or without food. Official administration instructions suggest that it should ideally be taken at the same time of day for consistency.


Q: Is it safe to drink alcohol in moderation while on Exforge?

A: Regulatory information indicates that both components of Exforge (amlodipine and valsartan) may have an additive effect when combined with alcohol (ethanol) in lowering blood pressure. This could potentially increase the risk of symptoms like dizziness, headache, or fainting, particularly when first starting treatment.


Q: What foods should be avoided when taking Exforge?

A: The official documents state that salt substitutes containing potassium should be avoided. This is because the valsartan component of Exforge can increase the risk of high potassium levels (hyperkalemia), and adding more potassium through salt substitutes can worsen this effect.


Q: Does Exforge interact with common pain relievers like ibuprofen?

A: Yes, Exforge is noted to interact with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), a class that includes medicines like ibuprofen. NSAIDs may reduce the blood pressure-lowering effect of Exforge and may also increase the risk of kidney function deterioration, especially in certain patient groups.


Q: What should I do if my blood pressure remains high even while taking Exforge?

A: The majority of the antihypertensive effect is often observed within two weeks of starting therapy or changing the dose. Official guidelines state that the dosage may be adjusted by a healthcare professional after at least one to two weeks of therapy if the blood pressure is not adequately controlled.


Q: Why did my doctor prescribe Exforge instead of two separate pills?

A: Exforge is a Fixed-Dose Combination (FDC) that contains two agents in one tablet. FDCs are often used because they can improve blood pressure control and may be more convenient for the patient, serving as a replacement for the same component doses taken previously as separate tablets.


Q: Does Exforge cause weight gain or loss?

A: While weight changes are not listed among the most common adverse reactions in key regulatory documents, both weight gain and weight loss have been reported as isolated cases in clinical trials.


Q: Can Exforge affect my heart rate?

A: The medicine has been associated with reports of palpitations (feeling a fast, fluttering, or pounding heart) and tachycardia (fast heart rate) in clinical trials. These effects are generally not classified as common adverse reactions.


Q: Does Exforge affect kidney function?

A: Drugs that inhibit the renin-angiotensin system (the valsartan component) can cause changes in kidney function, including the potential for acute kidney problems. Monitoring of renal function may be recommended, particularly for susceptible individuals, as documented in the official labeling.


Q: Can men experience sexual side effects from Exforge?

A: Sexual side effects have been reported in both male and female patients. Specifically, erectile dysfunction (impotence) has been reported in men during clinical trials and post-marketing experience.


Q: Can Exforge be split in half if the pill is difficult to swallow?

A: The product is described as a film-coated tablet and is not explicitly marked as scored or approved for splitting in its description. Regulatory standards suggest that tablets should not be split unless the product's labeling specifically indicates it is approved for splitting.


Q: Are there any changes I should expect in my urine when starting Exforge?

A: While not common, infrequent adverse reactions reported in clinical trials have included hematuria (blood in the urine), pollakiuria (frequent urination), and polyuria (excessive urination).


Q: Does Exforge make you feel tired or fatigued?

A: Yes, fatigue and asthenia (physical weakness or lack of energy) are listed among the common adverse reactions reported in clinical trials for Exforge.


Q: Can Exforge cause muscle cramps or spasms?

A: Muscle spasms and muscle cramps have been reported as adverse reactions in clinical trials, according to official safety information, although they are not typically listed among the most common effects.


Q: Is it safe for women who are planning pregnancy to take Exforge?

A: Because the valsartan component is known to cause injury and death to the developing fetus, regulatory bodies advise that if a woman is planning pregnancy, she should consult her healthcare provider to review her medication before conception.


Q: Are there special considerations for children or teenagers taking Exforge?

A: Official labeling generally does not recommend the use of Exforge in patients under 18 years of age. This is because the safety and efficacy of the fixed-dose combination have not been established in the pediatric population.


Q: Does Exforge interact with cold and flu medications?

A: Regulatory documents do not mention 'cold and flu medications' as a single class, but they do warn of potential interactions with certain common ingredients found in them, such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and other drugs that affect blood pressure.


Q: Why is it important to have blood tests while taking Exforge?

A: Official labeling indicates that monitoring blood tests may be recommended to check for potential changes in kidney function and serum potassium levels. These monitoring requirements are documented warnings and precautions related to the valsartan component.


Q: Can Exforge affect my cholesterol levels?

A: While not a primary effect, hypercholesterolemia (high cholesterol) has been observed as an uncommon metabolic adverse reaction in clinical trials. Furthermore, the drug has a known interaction with the cholesterol-lowering medication simvastatin.


Q: Is Exforge a diuretic (water pill)?

A: No. Exforge is officially classified as an Angiotensin II Inhibitor with a Calcium Channel Blocker. It is a combination product that achieves its blood pressure-lowering effect through two different mechanisms and does not contain a diuretic component.


Q: Can taking Exforge cause changes in mood or anxiety?

A: Psychiatric adverse reactions have been reported, though they are not common. These include reports of depression, insomnia (sleep disorders), mood swings, and anxiety.

How should Exforge be stored and disposed of?

How to Store and Dispose of Exforge

Exforge (amlodipine and valsartan) must be stored according to specific regulatory requirements to maintain its stability and effectiveness. The tablets must be kept at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Brief excursions outside of this range are permitted, but the medicine should not be exposed to prolonged high heat or cold.

Container and Safety

The medication must be stored in the original container and kept out of the reach of children.

Disposal

Unused or expired Exforge must not be disposed of in household trash or poured down a sink. Disposal must follow local guidelines for pharmaceutical waste, which typically involves returning the product to a pharmacy or using a community drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Exforge found in:

A-Z Index: